www.stopafib.org
To be notified when new conference videos are posted, or for the latest afib news, sign up at www.stopafib.org
2015 Get in Rhythm. Stay in Rhythm.™ Atrial Fibrillation Patient Conference
In his talk about Treating Atrial Fibrillation with Medications at the 2015 Get in Rhythm. Stay in Rhythm.™ Atrial Fibrillation Patient Conference, Dr. Mintu Turakhia of Stanford University covered:
• How does the doctor decide what medications to recommend?
•Rate control vs. rhythm control [1:15]
• Consider restoring sinus rhythm when AF causes symptoms [2:43]
• Whether rhythm control should be used without overt symptoms [4:45]
• Rapid heart rate may not be obvious [4:55]
• Heart failure from AF may not be obvious [5:50]
• Mechanisms to see how fast heart rates lead to failure [8:05]
• Cycle of AF and heart failure [8:27]
• How does doctor decide what to recommend [8:47]
• Severity of AF influences decisions [13:16]
• Severity defined by behavior, then burden [14:40]
• Natural time course of AF [16:00]
• Classification of AF [16:30]
• What drugs can be used [17:37]
• Typical doses of antiarrhythmic drugs [18:33]
o Sotalol and dofetilide [18:52]
o Amiodarone [19:47] and dronedarone [20:29]
o How doctors decide what rate control agents to use first-line [20:53]
o Digoxin - TREAT-AF study [21:38]
• How structural heart disease vs. no structural heart disease relates to drug choice [18:06]
• AF and heart failure
Video watching time is approximately 25 minutes.
Dr. Turakhia is a cardiac electrophysiologist, outcomes researcher, and Assistant Professor of Medicine and of Health Research and Policy at Stanford University. He is Chief of Cardiac Electrophysiology at the Palo Alto VA Health Care System and is an Associate Investigator at the Center for Innovation to Implementation.
In his clinical role, Dr. Turakhia performs complex catheter ablation (primarily for AF), device implantation, and left atrial appendage occlusion. Dr. Turakhia has an active clinical research program, with funding from AHA, VA, NIH, the medical device industry, and foundations. His research program aims to improve the treatment of heart rhythm disorders, with an emphasis on atrial fibrillation, by evaluating quality and variation of care, comparative and cost-effectiveness of therapies, and predicting outcomes such as stroke.
Dr. Turakhia has extensive expertise in using large administrative and claims databases for this work. His other research interests include technology assessment of new device based therapies and the impact of changing health policy and reform on the delivery of arrhythmia care. Dr. Turakhia has over 70 publications and is a Fellow of the American Heart Association, American College of Cardiology, and Heart Rhythm Society.
Transcript www.stopafib.or...